FDA Approves First Drug to Treat Two Forms of MS

On March 28, 2017, the United States Food and Drug Administration (FDA) announced the approval of Ocrevus™ (ocrelizumab) for the treatment of two types of multiple sclerosis (MS): relapsing forms of MS (RMS) and primary-progressive MS (PPMS). This is the first time that a medication for MS has been approved for two types of the […]

Read News Article

Patient Access Network (PAN) Foundation and MSAA Launch Alliance to Support People Living with MS

The Patient Access Network (PAN) Foundation and Multiple Sclerosis Association of America (MSAA) today announced they are launching a new alliance to offer a broad range of support for people living with multiple sclerosis (MS). Working together, the PAN Foundation and MSAA will ensure that people living with multiple sclerosis have access to both financial […]

Read News Article

Ira Levee Appointed to the Multiple Sclerosis Association of America’s Board of Directors

The Multiple Sclerosis Association of America (MSAA) is pleased to announce its newest member of its Board of Directors, Ira M. Levee of West Orange, New Jersey. Mr. Levee is an accomplished attorney with extensive experience in bankruptcy law as well as commercial and bankruptcy litigation. Presently, Mr. Levee is a Senior Legal Editor at […]

Read News Article

Multiple Sclerosis Association of America and Antidote Technologies Team Up to Increase Awareness of Clinical Trials

The Multiple Sclerosis Association of America (MSAA), a national nonprofit organization and leading resource for the MS community, and Antidote Technologies, a digital health company, have announced a partnership to increase awareness of MS clinical trials and enable people to easily access this important information. The Antidote Match clinical trial search tool will now be available on MSAA’s website, allowing visitors to find trials that are right for them or their loved ones in minutes, just by answering a few questions.

Read News Article

Ocrevus™ (Ocrelizumab) Phase III Trial Results Published

The results from three Phase III studies of the experimental medication Ocrevus™ (ocrelizumab) were published in the December 21, 2016 online issue of the New England Journal of Medicine (NEJM). Although initial findings had been presented at the 2015 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) Annual Meeting and other MS conferences, […]

Read News Article

FDA Extends Review of Ocrevus™ (ocrelizumab)

On December 20, 2016, Genentech, a member of the Roche group, announced that the United States Food and Drug Administration (FDA) had extended the review period of Ocrevus™ (ocrelizumab) for the treatment of relapsing forms of MS (RMS) and primary-progressive MS (PPMS). This extension was needed to allow more time for the FDA to review […]

Read News Article

Highlights from the 2016 ECTRIMS Annual Meeting

More than 9,000 clinicians and researchers attended the 2016 meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London, England. This year’s conference took place from September 14-17. The meeting was full of ground-breaking studies that promise to continue to advance the field toward better treatments for individuals with multiple […]

Read News Article

Make Your Voice Heard on MS Treatment

The Institute for Clinical and Economic Review (ICER) is currently conducting a review of disease-modifying therapies for relapsing-remitting and primary-progressive forms of multiple sclerosis. Insurers may use ICER recommendations to develop or change their approved drug lists, which could potentially improve or restrict access to MS medications for people living with MS. To ensure that […]

Read News Article